CORE--SOLID TUMOR PHARMACOLOGY

核心--实体瘤药理学

• 批准号: 6101973
• 负责人: CLINTON F STEWART
• 金额: $ 16.71万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2000-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6101973
• 关键词: DNA topoisomerases; antineoplastics; bioassay; biomedical facility; enzyme linked immunosorbent assay; high performance liquid chromatography; histology; microdialysis; neoplasm /cancer pharmacology; pediatric neoplasm /cancer; pharmacokinetics; topotecan; western blottings

The functions of the Solid Tumor Pharmacology Core are to: A. Perform assays to quantitate drug and drug metabolite concentrations in biological specimens collected from animals and patients as part of preclinical and clinical pharmacokinetic studies within this Program. B. Perform additional special laboratory procedures as required to support the projects included in this Program. C. Perform appropriate biochemical assays (e.g., immunoblot analysis for topoisomerase I, catalytic activity of topoisomerase I) on preclinical and clinical samples to evaluate the activity of anticancer drugs to provide more comprehensive pharmacodynamic analyses. D. Maintain computer databases of data from analyses performed in the Solid Tumor Pharmacology Core, and generate data retrievals and reports as required. E. Analyze pharmacokinetic data obtained from preclinical and clinical pharmacokinetic studies, and fit appropriate pharmacokinetic and pharmacodynamic models to the data, as requested by investigators in this Program.

实体瘤药理学核心的功能是： A. 进行测定以定量药物和药物代谢物 从动物采集的生物样本中的浓度 作为临床前和临床药代动力学研究的一部分的患者 在本计划内。 B. 根据需要执行额外的特殊实验室程序 支持本计划中包含的项目。 C. 进行适当的生化测定（例如，免疫印迹分析 对于拓扑异构酶 I，拓扑异构酶 I 的催化活性） 临床前和临床样本以评估抗癌活性 药物提供更全面的药效学分析。 D. 维护计算机数据库中进行的分析数据 实体瘤药理学核心，并生成数据检索和报告 根据需要。 E. 分析从临床前和临床获得的药代动力学数据 药代动力学研究，并拟合适当的药代动力学和 根据研究人员的要求，对数据进行药效学模型 这个程序。